{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:51:52Z","timestamp":1779933112330,"version":"3.53.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"vor","delay-in-days":3486,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.2353\/jmoldx.2010.090137","type":"journal-article","created":{"date-parts":[[2010,4,29]],"date-time":"2010-04-29T22:40:48Z","timestamp":1272580848000},"page":"512-519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["A Real-Time Polymerase Chain Reaction Assay for Rapid, Sensitive, and Specific Quantification of the JAK2V617F Mutation Using a Locked Nucleic Acid-Modified Oligonucleotide"],"prefix":"10.1016","volume":"12","author":[{"given":"Barbara","family":"Denys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"El Housni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedel","family":"Nollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Verhasselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Philipp\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2353\/jmoldx.2010.090137_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-007-0403-6","article-title":"The diagnosis of BCR\/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers","volume":"87","author":"Haferlach","year":"2008","journal-title":"Ann Hematol"},{"key":"10.2353\/jmoldx.2010.090137_bib2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.2353\/jmoldx.2010.090137_bib3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.2353\/jmoldx.2010.090137_bib4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.2353\/jmoldx.2010.090137_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.2353\/jmoldx.2010.090137_bib6","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2010.090137_bib7","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.2353\/jmoldx.2010.090137_bib8","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2010.090137_bib9","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2 V617F mutation in essential thrombocythemia","volume":"19","author":"Antonioli","year":"2005","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2010.090137_bib10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/10428190801895360","article-title":"JAK and MPL mutations in myeloid malignancies","volume":"49","author":"Tefferi","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.2353\/jmoldx.2010.090137_bib11","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2010.090137_bib12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2010.090137_bib13","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","article-title":"Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia","volume":"108","author":"Scott","year":"2006","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2010.090137_bib14","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2010.090137_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","article-title":"Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia","volume":"93","author":"Antonioli","year":"2008","journal-title":"Haematologica"},{"key":"10.2353\/jmoldx.2010.090137_bib16","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1600-0609.2007.00960.x","article-title":"The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis\u2013impact on disease phenotype","volume":"79","author":"Larsen","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.2353\/jmoldx.2010.090137_bib17","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"},{"key":"10.2353\/jmoldx.2010.090137_bib18","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2\u2013V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2010.090137_bib19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2010.090137_bib20","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2010.090137_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.leu.2404948","article-title":"JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials","volume":"22","author":"Pardanani","year":"2008","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2010.090137_bib22","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2010.090137_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2353\/jmoldx.2006.060007","article-title":"JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology","volume":"8","author":"Steensma","year":"2006","journal-title":"J Mol Diagn"},{"key":"10.2353\/jmoldx.2010.090137_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3233\/CBM-2007-3605","article-title":"Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis","volume":"3","author":"Sutton","year":"2007","journal-title":"Cancer Biomark"},{"key":"10.2353\/jmoldx.2010.090137_bib25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.leu.2404007","article-title":"Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"20","author":"McClure","year":"2006","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2010.090137_bib26","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1309\/LW7Q3739RBRMBXXP","article-title":"Comparative evaluation of three JAK2V617F mutation detection methods","volume":"128","author":"Frantz","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.2353\/jmoldx.2010.090137_bib27","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1309\/1U61JVXTLPPQ7YP1","article-title":"A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation","volume":"127","author":"Tan","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.2353\/jmoldx.2010.090137_bib28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1309\/TK0XL917XK2VLRPQ","article-title":"Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis","volume":"125","author":"Murugesan","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.2353\/jmoldx.2010.090137_bib29","doi-asserted-by":"crossref","first-page":"997","DOI":"10.5858\/2006-130-997-DOTJMI","article-title":"Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system","volume":"130","author":"Olsen","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"10.2353\/jmoldx.2010.090137_bib30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2353\/jmoldx.2007.060133","article-title":"Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"9","author":"Chen","year":"2007","journal-title":"J Mol Diagn"},{"key":"10.2353\/jmoldx.2010.090137_bib31","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2006-08-039909","article-title":"Monitoring of the JAK2\u2013V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis","volume":"109","author":"Kroger","year":"2007","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2010.090137_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2353\/jmoldx.2007.060083","article-title":"Development of a quantitative real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation","volume":"9","author":"Wolstencroft","year":"2007","journal-title":"J Mol Diagn"},{"key":"10.2353\/jmoldx.2010.090137_bib33","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2353\/jmoldx.2007.060125","article-title":"Quantitative determination of JAK2 V617F by TaqMan: an absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders","volume":"9","author":"Hammond","year":"2007","journal-title":"J Mol Diagn"},{"key":"10.2353\/jmoldx.2010.090137_bib34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/hon.800","article-title":"A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood","volume":"24","author":"Poodt","year":"2006","journal-title":"Hematol Oncol"},{"key":"10.2353\/jmoldx.2010.090137_bib35","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2007.06497.x","article-title":"The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders","volume":"136","author":"Larsen","year":"2007","journal-title":"Br J Haematol"},{"key":"10.2353\/jmoldx.2010.090137_bib36","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1373\/clinchem.2006.066886","article-title":"Combined locked nucleic acid and molecular beacon technologies for sensitive detection of the JAK2V617F somatic single-base sequence variant","volume":"52","author":"Sidon","year":"2006","journal-title":"Clin Chem"},{"key":"10.2353\/jmoldx.2010.090137_bib37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/humu.10228","article-title":"Enhanced allele-specific PCR discrimination in SNP genotyping using 3\u2032 locked nucleic acid (LNA) primers","volume":"22","author":"Latorra","year":"2003","journal-title":"Hum Mutat"},{"key":"10.2353\/jmoldx.2010.090137_bib38","series-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","article-title":"World Health Organization Classification of Tumours","author":"Jaffe","year":"2001"},{"key":"10.2353\/jmoldx.2010.090137_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3324\/haematol.13486","article-title":"Concordance of assays designed for the quantification of JAK2V617F: a multicenter study","volume":"94","author":"Lippert","year":"2009","journal-title":"Haematologica"},{"key":"10.2353\/jmoldx.2010.090137_bib40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.leu.2404081","article-title":"JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders","volume":"20","author":"Quentmeier","year":"2006","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2010.090137_bib41","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/sj.leu.2404588","article-title":"Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F)","volume":"21","author":"Hermouet","year":"2007","journal-title":"Leukemia"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157810600931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157810600931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:12:13Z","timestamp":1761502333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157810600931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S1525157810600931"],"URL":"https:\/\/doi.org\/10.2353\/jmoldx.2010.090137","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Real-Time Polymerase Chain Reaction Assay for Rapid, Sensitive, and Specific Quantification of the JAK2V617F Mutation Using a Locked Nucleic Acid-Modified Oligonucleotide","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.2353\/jmoldx.2010.090137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Society for Investigative Pathology and Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}